Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the scientific ...
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the stocks that could 10x over the next 5 years. On March 3, H.C. Wainwright ...
Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The ...
Beam Therapeutics recently announced that it secured a standby license with Kobe University and Bio Palette for key gene-editing patents and confirmed the upcoming resignation of board member Carole ...
The last time I wrote about Beam Therapeutics Inc. (BEAM) it was in a Seeking Alpha article entitled "Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases." I rated the ...
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across ...
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating and $80 price target for Beam Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results